CytRx Stock Plunges After FDA Rejection
CytRx Corp. shares plunged 62% after the FDA rejected a drug application from a Danish biotech firm that had partnered with CytRx.
More from California Business
North California Record
Following state appellate ruling involving ADA claims, further relief urged at federal level
California Business
•
Dec 5, 2022
FresnoBee | Business
Here's How to Keep Winter Utility Bills Down as Energy Costs Rise
California Business
•
Dec 5, 2022
East Bay Times | Business
Released Twitter emails show how employees debated how to handle 2020 New York Post Hunter Biden story
California Business
•
Dec 5, 2022